Alessio Schirone

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Angelo Di Leo, Stephen Johnston, Keun Seok Lee et al. · The Lancet Oncology · 2017 · 381 citations

Medicine, Oncology, Pharmacology +16

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

PierFranco Conte, Antonio Frassoldati, Giancarlo Bisagni et al. · Annals of Oncology · 2018 · 155 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 88 citations · Full text

Medicine, Endocrinology, Oncology +11

Abstract S4-07: BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment

Angelo Di Leo, Keun Seok Lee, Eva Ciruelos et al. · Cancer Research · 2017 · 55 citations

Medicine, Oncology, Pharmacology +17

Cell-free DNA detected by “liquid biopsy” as a potential prognostic biomarker in early breast cancer

Roberta Maltoni, Valentina Casadio, Sara Ravaioli et al. · Oncotarget · 2017 · 31 citations · Full text

Medicine, Molecular Biology, Oncology +17